Nu-Med Plus (NUMD) Capital Expenditures (2012 - 2018)

Nu-Med Plus (NUMD) reported Capital Expenditures of $1.0 for Q4 2018, up 100.09% sequentially from -$1101.0 in Q4 2014.

Nu-Med Plus (NUMD) Capital Expenditures (2012 - 2018) Analysis & Trends

Nu-Med Plus (NUMD) has 4 years of Capital Expenditures data on file, last reported at $1.0 in Q4 2018.

For the quarter ending Q4 2018, Capital Expenditures changed N/A year-over-year to $1.0; the trailing twelve-month figure through Dec 2019 stood at $1.0 (changed 0.0% YoY), and the FY2018 full-year result was -$5025.0, changed N/A from the prior year.
Capital Expenditures rose to $1.0 in Q4 2018, from -$1101.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $1.0 in Q4 2018 to a low of -$1101.0 in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	399.00 Mn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	166.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	488.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	177.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	64.90 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	76.60 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	-85.46 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	178.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2018	1.00
Dec 31, 2018	1.00
Dec 31, 2014	-1,101.00
Dec 31, 2014	-1,101.00
Dec 31, 2013	27,240.00
Dec 31, 2013	27,240.00
Sep 30, 2013	1,679.00
Sep 30, 2013	1,679.00
Dec 31, 2012	-36.00
Dec 31, 2012	-36.00
Sep 30, 2012	1.00
Sep 30, 2012	1.00
Jun 30, 2012	18,835.00
Jun 30, 2012	18,835.00